Related Experiment Videos
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
Pasi A Jänne1, Ana M Borras, Yanan Kuang
1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. pjanne@partners.org
Summary
A new SURVEYOR method rapidly screens for epidermal growth factor receptor (EGFR) mutations in lung cancer with 100% sensitivity. This technique is superior to direct sequencing, especially for small or undissected specimens.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) mutations are key targets for lung cancer therapies like gefitinib and erlotinib.
- Current DNA sequencing methods for EGFR mutations are limited by sensitivity and specimen requirements.
Purpose of the Study:
- To introduce and evaluate a sensitive screening method for EGFR mutations.
- To overcome limitations of existing DNA sequencing techniques for EGFR mutation detection.
Main Methods:
- Screened 178 non-small cell lung cancer specimens for EGFR mutations (exons 18-21) using SURVEYOR endonuclease.
- Employed high-performance liquid chromatography (HPLC) with Transgenomic WAVE HS system.
- Validated findings with direct DNA sequencing on 160 specimens.
Main Results:
- Detected EGFR mutations in various specimen types, including undissected formalin-fixed, paraffin-embedded samples.
- Achieved 100% sensitivity and 87% specificity compared to direct sequencing.
- Identified 7 additional mutations missed by direct sequencing, highlighting SURVEYOR's enhanced detection capabilities.
Conclusions:
- SURVEYOR analysis offers a rapid and highly sensitive method for EGFR mutation screening.
- Demonstrated 100% sensitivity and negative predictive value for the SURVEYOR method.
- This scanning technique is advantageous over direct sequencing for challenging specimens, including undissected formalin-fixed, paraffin-embedded samples.